Is cardioprotection with GLP-1 receptor agonists a class effect?
نویسندگان
چکیده
منابع مشابه
Basal Insulin Use With GLP-1 Receptor Agonists
IN BRIEF The combination of basal insulin and a glucagon-like peptide 1 receptor agonist is becoming increasingly common and offers several potential benefits to patients with type 2 diabetes. Clinical studies have demonstrated improved glycemic control and low risks of hypoglycemia and weight gain with the combination, which provides a safe and effective alternative to basal-bolus insulin with...
متن کاملThe Cardiovascular Effects of GLP-1 Receptor Agonists
Glucagon-like peptide-1 receptor (GLP-1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety. GLP-1 receptors have also been identified in the heart, kidneys, and blood vessels, leading to the hypothesis that GLP-1R agonists may affect cardiov...
متن کاملDifferentiating between GLP-1 receptor agonists and DPP-4 inhibitors
Article points 1. Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the activity of DPP-4 to prolong the effects of native glucagon-like peptide-1 (GLP-1), whereas GLP-1 receptor agonists (GLP-1RAs) provide activation of the GLP-1 receptor while remaining resistant to degradation by DPP-4. 2. Both DPP-4Is and GLP-1RAs provide glycaemic control in people with type 2 diabetes, and GLP-1RAs are ...
متن کاملGLP-1 receptor agonists and heart failure in diabetes.
The prevalence of heart failure (HF) is increasing in patients with type 2 diabetes (T2D), and glucose-lowering agents have distinctive effects on the risk of developing HF that requires hospitalization. Such an increased risk has been consistently reported with thiazolidinediones (glitazones) and perhaps also with the dipeptidyl peptidase (DPP)-4 inhibitor saxagliptin (at least in SAVOR - TIMI...
متن کاملIs there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Several GLP-1 receptor agonists are currently available for treatment of type 2 diabetic patients. Based on their pharmacokinetic/pharmacodynamic profile, these drugs are classified as short-acting GLP-1 receptor agonists (exenatide and lixisenatide) or long-acting GLP-1 receptor agonists (exenatide-LAR, liraglutide, albiglutide, and dulaglutide). In clinical practice, they are also classified ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Preventive Cardiology
سال: 2020
ISSN: 2047-4873,2047-4881
DOI: 10.1093/eurjpc/zwaa103